Save time and jump to the most important pieces.
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
Benchmark analyst Robert Wasserman reiterates Intensity Therapeutics (NASDAQ:INTS) with a Speculative Buy and maintains $12 price target.
424B5 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
8-K - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
424B5 - INTENSITY THERAPEUTICS, INC. (0001567264) (Filer)
SHELTON, Conn., May 15, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces the appointment of Thomas Dubin, J.D., MPH, to the Intensity Board of Directors, effective May 14, 2024. Mr. Dubin will serve as a member of the Audit Committee of the Board. In connection with Mr. Dubin's appointment, the size of the Board was increased from four directors to five. Of these five directors, four are independent pursuant to Nas
Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held development and commercial stage biopharmaceutical companies SHELTON, Conn., Dec. 12, 2023 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced the appointment of Joseph Talamo as Chief Financial Officer (CFO). Mr. Talamo will be working at Intensity headquarters as a full time employee. An accomplished executive with more than
SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)
SC 13G - INTENSITY THERAPEUTICS, INC. (0001567264) (Subject)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
4 - INTENSITY THERAPEUTICS, INC. (0001567264) (Issuer)
SHELTON, Conn., Nov. 21, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or the "Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor for the issuance and sale of 1,237,113 shares of its common stock in a registered direct offering at a purchase price of $2.425 per share.
Phase 1/2 data showed a median overall survival ("mOS") of 21.3 months versus a synthetic control of 6.7 months, an increase in T-cell activation, and favorable safety profile for patients receiving INT230-6 alone INVINCIBLE-3 Study is recruiting and expected to enroll 333 patients with leiomyosarcoma, liposarcoma and undeferential pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study have been received in the U.S., Canada, Europe and Australia SHELTON, Conn., Nov. 18, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. (NASDAQ:INTS), ("Intensity" or "the Company") a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based i
First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces third quarter 2024 financial results and provides a corporate update. Corporate Update INVINCIBLE-3 Study: a Phase 3 open-label, rand
First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics, Inc. ("Intensity" or "the Company") (NASDAQ:INTS), a late-stage clinical biotechnology company focused on the discovery and development of proprietary, novel immune-based intratumoral cancer therapies designed to kill tumors and increase immune system recognition of cancers, announces third quarter 2024 financial results and provides a corporate update. Corporate Update INVINCIBLE-3 Study: a Phase 3 open-label, rand